Handelen Alimera Sciences, Inc. - ALIM CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.24 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Belangrijkste statistieken
| Prev. Close* | 2.49 |
| Open* | 2.51 |
| 1-Jaarlijkse Verandering* | -55.81% |
| Dagelijks bereik* | 2.38 - 2.51 |
| 52 wekelijks bereik | 1.30-7.92 |
| Weekgemiddelde volume (10 dagen) | 107.41K |
| Gemiddeld volume (3 maanden) | 13.10M |
| Marktkapitalisatie | 19.10M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 7.40M |
| Omzet | 55.78M |
| EPS | -2.44 |
| Dividend (opbrengst %) | N/A |
| Beta | 1.39 |
| Volgende inkomsten datum | Jul 25, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Jun 9, 2023 | 2.41 | -0.03 | -1.23% | 2.44 | 2.52 | 2.35 |
| Jun 8, 2023 | 2.49 | -0.15 | -5.68% | 2.64 | 2.65 | 2.41 |
| Jun 7, 2023 | 2.62 | -0.05 | -1.87% | 2.67 | 2.71 | 2.57 |
| Jun 6, 2023 | 2.75 | 0.10 | 3.77% | 2.65 | 2.89 | 2.64 |
| Jun 5, 2023 | 2.71 | 0.18 | 7.11% | 2.53 | 2.80 | 2.53 |
| Jun 2, 2023 | 2.57 | 0.06 | 2.39% | 2.51 | 2.66 | 2.50 |
| Jun 1, 2023 | 2.52 | -0.08 | -3.08% | 2.60 | 2.60 | 2.51 |
| May 31, 2023 | 2.67 | 0.19 | 7.66% | 2.48 | 2.67 | 2.48 |
| May 30, 2023 | 2.52 | 0.05 | 2.02% | 2.47 | 2.55 | 2.47 |
| May 26, 2023 | 2.49 | 0.08 | 3.32% | 2.41 | 2.52 | 2.35 |
| May 25, 2023 | 2.48 | -0.02 | -0.80% | 2.50 | 2.51 | 2.37 |
| May 24, 2023 | 2.41 | 0.23 | 10.55% | 2.18 | 2.42 | 2.14 |
| May 23, 2023 | 2.32 | -0.19 | -7.57% | 2.51 | 2.55 | 2.21 |
| May 22, 2023 | 2.45 | 0.28 | 12.90% | 2.17 | 2.72 | 2.15 |
| May 19, 2023 | 2.23 | 0.12 | 5.69% | 2.11 | 2.30 | 2.02 |
| May 18, 2023 | 2.34 | -0.26 | -10.00% | 2.60 | 3.05 | 2.26 |
| May 17, 2023 | 1.93 | 0.11 | 6.04% | 1.82 | 1.94 | 1.78 |
| May 16, 2023 | 1.79 | 0.21 | 13.29% | 1.58 | 1.92 | 1.58 |
| May 15, 2023 | 1.57 | -0.03 | -1.88% | 1.60 | 1.68 | 1.56 |
| May 12, 2023 | 1.56 | -0.05 | -3.11% | 1.61 | 1.64 | 1.55 |
Alimera Sciences, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Wednesday, July 12, 2023 | ||
| Tijd (UTC) (UTC) 13:30 | Land US
| Evenement Alimera Sciences Inc Annual Shareholders Meeting Alimera Sciences Inc Annual Shareholders MeetingForecast -Previous - |
| Tuesday, July 25, 2023 | ||
| Tijd (UTC) (UTC) 12:30 | Land US
| Evenement Q2 2023 Alimera Sciences Inc Earnings Release Q2 2023 Alimera Sciences Inc Earnings ReleaseForecast -Previous - |
| Monday, November 13, 2023 | ||
| Tijd (UTC) (UTC) 13:30 | Land US
| Evenement Q3 2023 Alimera Sciences Inc Earnings Release Q3 2023 Alimera Sciences Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 54.129 | 59.029 | 50.82 | 53.943 | 46.599 |
| Inkomsten | 54.129 | 59.029 | 50.82 | 53.943 | 46.599 |
| Kosten van opbrengsten, totaal | 7.977 | 7.03 | 6.941 | 6.626 | 4.308 |
| Brutowinst | 46.152 | 51.999 | 43.879 | 47.317 | 42.291 |
| Totale bedrijfskosten | 65.769 | 57.438 | 51.321 | 59.217 | 58.035 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 38.858 | 35.843 | 32.036 | 38.958 | 38.042 |
| Onderzoek & Ontwikkeling | 16.228 | 13.778 | 9.668 | 10.992 | 11.274 |
| Depreciation / Amortization | 2.706 | 2.579 | 2.676 | 2.641 | 2.645 |
| Ongebruikelijke uitgaven (inkomsten) | 0 | -1.792 | 0 | 1.766 | |
| Bedrijfsresultaat | -11.64 | 1.591 | -0.501 | -5.274 | -11.436 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -5.789 | -4.997 | -4.906 | -4.953 | -4.84 |
| Netto inkomen voor belastingen | -18.079 | -3.934 | -5.407 | -10.227 | -16.276 |
| Netto inkomen na belastingen | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
| Netto inkomen voor extra. Posten | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
| Netto inkomen | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
| Verwaterd Netto Inkomen | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
| Verwaterd Gewogen Gemiddelde Aandelen | 6.99685 | 6.59524 | 5.11766 | 4.7702 | 5.91587 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.58788 | -0.6629 | -1.04325 | -2.18921 | 3.71002 |
| Verwaterde Genormaliseerde Winst per Aandeel | -2.58788 | -0.83951 | -1.04325 | -2.18921 | 3.90406 |
| Other Operating Expenses, Total | |||||
| Totale buitengewone posten | 0 | 0 | |||
| Total Adjustments to Net Income | 0 | 38.33 | |||
| Overige, Netto | -0.65 | -0.528 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 13.546 | 14.029 | 13.598 | 14.604 | 11.898 |
| Inkomsten | 13.546 | 14.029 | 13.598 | 14.604 | 11.898 |
| Kosten van opbrengsten, totaal | 2.028 | 2.125 | 2.006 | 2.166 | 1.68 |
| Brutowinst | 11.518 | 11.904 | 11.592 | 12.438 | 10.218 |
| Totale bedrijfskosten | 16.848 | 16.137 | 17.009 | 16.578 | 16.045 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 9.975 | 9.099 | 9.856 | 9.81 | 10.093 |
| Onderzoek & Ontwikkeling | 4.164 | 4.23 | 4.483 | 3.932 | 3.583 |
| Depreciation / Amortization | 0.681 | 0.683 | 0.664 | 0.67 | 0.689 |
| Bedrijfsresultaat | -3.302 | -2.108 | -3.411 | -1.974 | -4.147 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -1.68 | -1.621 | -1.567 | -1.345 | -1.256 |
| Netto inkomen voor belastingen | -4.968 | -3.781 | -5.245 | -3.098 | -5.955 |
| Netto inkomen na belastingen | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
| Netto inkomen voor extra. Posten | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
| Netto inkomen | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
| Verwaterd Netto Inkomen | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
| Verwaterd Gewogen Gemiddelde Aandelen | 7.03223 | 7.00032 | 6.99658 | 6.99971 | 6.99074 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.70845 | -0.53998 | -0.75137 | -0.44502 | -0.85184 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.70845 | -0.53998 | -0.75137 | -0.44502 | -0.85184 |
| Ongebruikelijke uitgaven (inkomsten) | 0 | 0 | 0 | ||
| Overige, Netto | 0.014 | -0.052 | -0.267 | 0.221 | -0.552 |
| Total Adjustments to Net Income | -0.014 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 29.413 | 42.16 | 34.906 | 32.745 | 34.848 |
| Geldmiddelen en kortetermijnbeleggingen | 5.274 | 16.51 | 11.208 | 9.426 | 13.043 |
| Geldmiddelen & Equivalenten | 5.274 | 16.51 | 11.208 | 9.426 | 13.043 |
| Totale Vorderingen, Netto | 19.612 | 19.128 | 17.2 | 19.331 | 17.259 |
| Accounts Receivable - Trade, Net | 19.612 | 19.128 | 17.2 | 19.331 | 17.259 |
| Total Inventory | 1.605 | 2.679 | 2.746 | 1.39 | 2.405 |
| Prepaid Expenses | 2.892 | 3.809 | 3.718 | 2.565 | 2.109 |
| Other Current Assets, Total | 0.03 | 0.034 | 0.034 | 0.033 | 0.032 |
| Total Assets | 42.602 | 58.52 | 50.855 | 50.309 | 54.108 |
| Property/Plant/Equipment, Total - Net | 3.92 | 4.493 | 2.358 | 2.047 | 1.355 |
| Property/Plant/Equipment, Total - Gross | 7.981 | 7.923 | 6.305 | 5.858 | 4.967 |
| Accumulated Depreciation, Total | -4.061 | -3.43 | -3.947 | -3.881 | -3.612 |
| Intangibles, Net | 8.957 | 10.897 | 12.838 | 14.783 | 16.723 |
| Other Long Term Assets, Total | 0.129 | 0.137 | 0.753 | 0.734 | 1.182 |
| Total Current Liabilities | 39.732 | 12.592 | 12.348 | 12.048 | 10.234 |
| Accounts Payable | 10.088 | 8.706 | 7.461 | 7.077 | 6.355 |
| Accrued Expenses | 3.998 | 3.617 | 3.197 | 4.716 | 3.643 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 25.646 | 0.269 | 1.69 | 0.255 | 0.236 |
| Other Current Liabilities, Total | |||||
| Total Liabilities | 63.41 | 61.125 | 58.833 | 54.754 | 51.386 |
| Total Long Term Debt | 18.683 | 43.08 | 42.922 | 38.752 | 38.178 |
| Long Term Debt | 18.683 | 43.08 | 42.408 | 38.658 | 37.873 |
| Capital Lease Obligations | 0.514 | 0.094 | 0.305 | ||
| Other Liabilities, Total | 4.995 | 5.453 | 3.563 | 3.954 | 2.974 |
| Total Equity | -20.808 | -2.605 | -7.978 | -4.445 | 2.722 |
| Preferred Stock - Non Redeemable, Net | 19.227 | 19.227 | 19.227 | 30.344 | 30.344 |
| Common Stock | 0.07 | 0.069 | 0.057 | 0.05 | 0.701 |
| Additional Paid-In Capital | 378.238 | 377.229 | 365.83 | 350.117 | 346.108 |
| Retained Earnings (Accumulated Deficit) | -415.388 | -397.281 | -392.539 | -383.863 | -373.42 |
| Other Equity, Total | -2.955 | -1.849 | -0.553 | -1.093 | -1.011 |
| Total Liabilities & Shareholders’ Equity | 42.602 | 58.52 | 50.855 | 50.309 | 54.108 |
| Total Common Shares Outstanding | 6.99551 | 6.93515 | 5.71937 | 4.96595 | 4.67193 |
| Total Preferred Shares Outstanding | 0.6 | 0.6 | 0.6 | 0.61015 | 0.61015 |
| Long Term Investments | 0.183 | 0.833 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 35.675 | 29.413 | 29.76 | 33.073 | 34.753 |
| Geldmiddelen en kortetermijnbeleggingen | 13.086 | 5.274 | 5.514 | 7.859 | 9.946 |
| Geldmiddelen & Equivalenten | 13.086 | 5.274 | 5.514 | 7.859 | 9.946 |
| Totale Vorderingen, Netto | 18.433 | 19.612 | 19.142 | 20.319 | 18.776 |
| Accounts Receivable - Trade, Net | 18.433 | 19.612 | 19.142 | 20.319 | 18.776 |
| Total Inventory | 1.215 | 1.605 | 1.786 | 1.656 | 2.452 |
| Prepaid Expenses | 2.91 | 2.892 | 3.29 | 3.208 | 3.546 |
| Other Current Assets, Total | 0.031 | 0.03 | 0.028 | 0.031 | 0.033 |
| Total Assets | 48.239 | 42.602 | 43.429 | 47.574 | 49.931 |
| Property/Plant/Equipment, Total - Net | 3.757 | 3.92 | 3.87 | 3.938 | 4.343 |
| Intangibles, Net | 8.479 | 8.957 | 9.446 | 9.935 | 10.419 |
| Other Long Term Assets, Total | 0.131 | 0.129 | 0.118 | 0.126 | 0.134 |
| Total Current Liabilities | 14.173 | 39.732 | 34.01 | 25.431 | 17.006 |
| Accounts Payable | 9.669 | 10.088 | 8.706 | 7.614 | 6.604 |
| Accrued Expenses | 4.241 | 3.998 | 3.661 | 3.316 | 3.046 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.263 | 25.646 | 21.643 | 14.501 | 7.356 |
| Total Liabilities | 67.155 | 63.41 | 61.507 | 59.909 | 58.534 |
| Total Long Term Debt | 44.312 | 18.683 | 22.492 | 29.297 | 36.245 |
| Long Term Debt | 44.152 | 18.683 | 22.492 | 29.297 | 36.245 |
| Capital Lease Obligations | 0.16 | ||||
| Other Liabilities, Total | 8.67 | 4.995 | 5.005 | 5.181 | 5.283 |
| Total Equity | -18.916 | -20.808 | -18.078 | -12.335 | -8.603 |
| Preferred Stock - Non Redeemable, Net | 7.728 | 19.227 | 19.227 | 19.227 | 19.227 |
| Common Stock | 0.074 | 0.07 | 0.07 | 0.07 | 0.07 |
| Additional Paid-In Capital | 378.146 | 378.238 | 378.005 | 377.847 | 377.541 |
| Retained Earnings (Accumulated Deficit) | -402.081 | -415.388 | -411.608 | -406.351 | -403.236 |
| Other Equity, Total | -2.783 | -2.955 | -3.772 | -3.128 | -2.205 |
| Total Liabilities & Shareholders’ Equity | 48.239 | 42.602 | 43.429 | 47.574 | 49.931 |
| Total Common Shares Outstanding | 7.39159 | 6.99551 | 6.99802 | 6.99546 | 6.99265 |
| Total Preferred Shares Outstanding | 0.012 | 0.6 | 0.6 | 0.6 | 0.6 |
| Long Term Investments | 0.197 | 0.183 | 0.235 | 0.502 | 0.282 |
| Other Current Liabilities, Total |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
| Geldmiddelen uit Operationele Activiteiten | -9.975 | -3.224 | -2.193 | -4.152 | -11.553 |
| Geldmiddelen uit Operationele Activiteiten | 2.706 | 2.579 | 2.676 | 2.641 | 2.645 |
| Deferred Taxes | 0.116 | 0.61 | 0.031 | 0.454 | -0.653 |
| Niet-Geldelijke Posten | 2.621 | -0.692 | 1.829 | 3.377 | 7.084 |
| Cash Taxes Paid | 0.232 | 0.112 | 0.11 | 0.239 | 0.239 |
| Contant Betaalde Rente | 4.489 | 4.302 | 4.556 | 4.419 | 3.571 |
| Veranderingen in het Operationeel Kapitaal | 2.689 | -1.349 | -1.39 | -0.181 | -4.247 |
| Geldmiddelen uit Investeringsactiviteiten | -0.255 | -0.621 | -0.62 | -0.174 | -0.175 |
| Kapitaaluitgaven | -0.255 | -0.621 | -0.62 | -0.174 | -0.175 |
| Geldmiddelen uit Financieringsactiviteiten | -0.302 | 9.823 | 3.882 | 0.869 | 0.95 |
| Financiering van Cash Flow Posten | -0.113 | 0 | -0.019 | -2.227 | -3.808 |
| Uitgifte (Aflossing) van aandelen, netto | 0.1 | 10.044 | 0.049 | 0.902 | 0.085 |
| Uitgifte (Aflossing) van Schulden, Netto | -0.289 | -0.221 | 3.852 | 2.194 | 4.673 |
| Wisselkoerseffecten | -0.708 | -0.676 | 0.714 | -0.159 | -0.248 |
| Nettowijziging in Geldmiddelen | -11.24 | 5.302 | 1.783 | -3.616 | -11.026 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -4.968 | -18.107 | -14.327 | -9.07 | -5.955 |
| Cash From Operating Activities | -2.209 | -9.975 | -9.724 | -7.811 | -6.213 |
| Cash From Operating Activities | 0.681 | 2.706 | 2.023 | 1.359 | 0.689 |
| Non-Cash Items | 0.507 | 2.621 | 2.095 | 1.318 | 1.027 |
| Cash Taxes Paid | 0 | 0.232 | 0.224 | 0.182 | 0.018 |
| Cash Interest Paid | 1.354 | 4.489 | 3.253 | 2.145 | 1.061 |
| Changes in Working Capital | 1.571 | 2.689 | 0.485 | -1.418 | -1.974 |
| Cash From Investing Activities | -0.009 | -0.255 | -0.171 | -0.041 | -0.149 |
| Capital Expenditures | -0.009 | -0.255 | -0.171 | -0.041 | -0.149 |
| Cash From Financing Activities | 9.998 | -0.302 | -0.109 | -0.164 | -0.062 |
| Financing Cash Flow Items | -3.123 | -0.113 | |||
| Issuance (Retirement) of Debt, Net | 2.373 | -0.289 | -0.164 | -0.204 | -0.062 |
| Foreign Exchange Effects | 0.033 | -0.708 | -0.998 | -0.638 | -0.141 |
| Net Change in Cash | 7.813 | -11.24 | -11.002 | -8.654 | -6.565 |
| Issuance (Retirement) of Stock, Net | 10.748 | 0.1 | 0.055 | 0.04 | |
| Deferred Taxes | 0.116 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| Velan Capital Investment Management LP | Investment Advisor/Hedge Fund | 22.4131 | 1659654 | 1401901 | 2023-05-17 | MED |
| Ocumension Therapeutics | Corporation | 15.4621 | 1144945 | 0 | 2023-04-24 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 8.9243 | 660832 | 0 | 2023-03-31 | MED |
| Caligan Partners, LP | Hedge Fund | 6.4657 | 478777 | 0 | 2023-05-17 | MED |
| Eiswirth (Richard S Jr) | Individual Investor | 4.3555 | 322518 | 500 | 2023-04-24 | LOW |
| HOOPP Investment Management | Pension Fund | 3.3762 | 250000 | 0 | 2023-03-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0071 | 148624 | 0 | 2023-03-31 | LOW |
| Ashman Philip | Individual Investor | 1.8004 | 133315 | 0 | 2023-04-24 | MED |
| Holland (David R) | Individual Investor | 1.4704 | 108880 | 500 | 2023-04-24 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.3693 | 101394 | -1100 | 2023-03-31 | HIGH |
| Skibsted (Russell L) | Individual Investor | 1.0196 | 75500 | 58000 | 2023-03-26 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5167 | 38262 | 0 | 2023-03-31 | LOW |
| Jones (John Philip) | Individual Investor | 0.4347 | 32186 | 372 | 2022-10-31 | |
| Millennium Management LLC | Hedge Fund | 0.3884 | 28762 | 16799 | 2023-03-31 | HIGH |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.2639 | 19542 | 0 | 2023-03-31 | MED |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.2471 | 18300 | 0 | 2023-03-31 | |
| Perritt Capital Management, Inc. | Investment Advisor | 0.2431 | 18000 | 0 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.175 | 12962 | 438 | 2023-03-31 | LOW |
| J.P. Morgan Securities LLC | Research Firm | 0.14 | 10364 | 9838 | 2023-03-31 | MED |
| Snisarenko (John) | Individual Investor | 0.135 | 10000 | 0 | 2023-04-24 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Alimera Sciences, Inc. Company profile
Over Alimera Sciences, Inc.
Alimera Sciences, Inc. is een farmaceutisch bedrijf. Het bedrijf houdt zich bezig met de commercialisering en ontwikkeling van op recept verkrijgbare oftalmologische geneesmiddelen. Het richt zich op ziekten die de achterkant van het oog of het netvlies aantasten. Het commerciële product van de Vennootschap, ILUVIEN, is een intravitreaal implantaat dat patiënten behandelt door het toedienen van een continue microdosis van het niet gepatenteerde corticosteroïde fluocinolone acetonide (FAc) in het oog, gedurende maximaal 36 maanden. Het is betrokken bij de ontwikkeling voor de behandeling van diabetisch maculair oedeem (DME). DME is een aandoening van het netvlies die voorkomt bij diabetici en kan leiden tot ernstig gezichtsverlies en blindheid. ILUVIEN kan ook worden gebruikt om herval te voorkomen bij terugkerende niet-infectieuze uveïtis die het achterste oogsegment aantast (NIU-PS). De Vennootschap brengt ILUVIEN rechtstreeks op de markt in de Verenigde Staten, Duitsland, het Verenigd Koninkrijk, Portugal en Ierland.
| Industry: | Biopharmaceuticals |
Ste 290
6120 Windward Parkway
ALPHARETTA
GEORGIA 30005
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen